October 08, 2015
3M signs strategic agreements with Impel to accelerate commercialization and cost effectiveness of POD technology platform and Impel’s growing portfolio of enhanced CNS products.
February 08, 2016
As patient preference and compliance are becoming increasingly important, transdermal patches are a great alternative for those who struggle with swallowing pills or want a more comfortable alternative to injections.
April 19, 2016
Technology aims to solve patient competence and adherence challenges, minimizing burden on health care providers and payers.
September 25, 2015
MedImmune, the global biologics research and development arm of AstraZeneca, and 3M Drug Delivery Systems, today announced a research collaboration focused on developing next generation toll-like receptor (TLR) agonists - promising agents that activate innate immune cells and enhance the visibility of cancer tumors.
June 05, 2015
Mylan becomes the first company to market a generic version of the UK's number one prescribed long-acting β2-agonist + inhaled corticosteroid pressurized metered-dose inhaler asthma therapy
February 23, 2015
3M Drug Delivery Systems introduces 3M™ Scotchpak™ White Release Liners and White Backing Film. These transdermal components provide high visibility and improve ease of use for patients and caregivers.
January 28, 2015
3M hollow microneedle device now available for clinical trials;
holds the potential to replace traditional injections
December 21, 2014
Study Meets Primary Endpoint of Reducing the Percentage of Patients with Incident Vertebral Fracture and Also Meets Important Secondary Endpoints: Adverse Events Consistent with Previous Clinical Experience
August 13, 2014
Opportunity to accelerate growth of dose counter technology in existing and future MDI developments
May 05, 2014
Investment adding 20% capacity, supporting future growth
May 01, 2014
March 28, 2014
3M Drug Delivery Systems announces the appointment of Cindy R. Kent as its new president and general manager
January 10, 2017
3M Drug Delivery Systems announces a new phase of an ongoing collaboration with Panacea Pharmaceuticals, Inc. in delivering an investigational therapeutic cancer vaccine directly to the dermis via the 3M™ Hollow Microstructured Transdermal System (hMTS).